HbA1c 检测市场，按类型（实验室检测、即时检测）、技术（免疫测定、色谱、硼酸亲和色谱、HPLC）、最终用途（医院、诊断实验室、家庭护理）-预测（2024 年- 2032 年） ）

在糖尿病盛行率上升的推动下，HbA1c 检测市场规模在 2024 年至 2032 年期间将以 8.6% 的速度扩大。根据国际糖尿病联盟的数据，2021 年，有 5.37 亿成年人（约十分之一）患有糖尿病。预计这一数字将大幅增加，到2030 年将达到6.43 亿，到2045 年将达到7.83 亿。有效糖尿病管理工具的需求激增。 HbA1c 测试可测量长期血糖水平，对于监测和管理糖尿病以及预防其併发症至关重要。

随着各国投资升级和扩大医疗设施，糖尿病诊断服务的可近性和品质正在提高。最先进设备的可用性增加和医疗保健服务系统的改进有助于更有效和更广泛的 HbA1c 检测。

HbA1c 检测产业根据类型、技术、最终用途和地区进行分类。

到 2032 年，基于实验室的检测领域将快速成长，因为它们因其高精度和可靠性而被认为是 HbA1c 测量的黄金标准。这些测试利用高效液相层析 (HPLC) 和免疫测定等先进技术来提供精确的结果，这对于有效的糖尿病管理至关重要。基于实验室的测试的稳健性，以及处理大量患者和提供全面诊断资讯的能力，使其成为医疗机构的首选。

到 2032 年，家庭护理领域将出现可观的增长。家庭护理测试设备的便利性使个人能够定期追踪他们的血糖水平，这对于有效的糖尿病管理至关重要。家庭测试技术的创新，例如用户友好的血糖仪和 HbA1c 家庭测试套件，使患者能够更轻鬆地进行测试并获得可靠的结果，而无需经常前往医疗机构。

在该地区完善的医疗基础设施以及人们对糖尿病及其管理的高度认识的推动下，欧洲 HbA1c 检测行业规模将在 2032 年之前稳步扩大。欧洲国家正在投资先进的诊断技术并加强医疗保健服务，以改善糖尿病照护。此外，旨在增加糖尿病筛检和早期检测的政府措施和医疗政策也有助于市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 糖尿病盛行率增加
    • 技术进步
    • 开发新颖的测试方法
  • 产业陷阱与挑战
    • 设备成本高
    • 严格的监理政策
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 战略展望矩阵

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 基于实验室的测试
• 即时护理 (POC) 测试

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 免疫测定
• 色谱法
• 酵素法检测
• 硼酸盐亲和层析
• 高效液相层析法
• 其他技术

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 家庭护理设置
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• ARKRAY, Inc.
• Bio-Rad Laboratories, Inc.
• Ceragem Medisys Inc.
• Danaher Corporation
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd.
• HUMAN
• Menarini Diagnostics s.r.l
• PTS Diagnostics
• Randox Laboratories Ltd.
• SAKAE CO. LTD.
• SEKISUI MEDICAL CO., LTD.
• Siemens Healthineers AG
• Trinity Biotech plc

The HbA1c Testing Market size will expand at 8.6% rate during 2024-2032, driven by the rising prevalence of diabetes. According to Internation Diabetes Federation, in 2021, 537 million adults, or approximately 1 in 10, were living with diabetes. This number is projected to increase significantly, reaching 643 million by 2030 and 783 million by 2045. With increasing rate of diabetes globally, driven by factors such as sedentary lifestyles, unhealthy diets, and aging populations, the demand for effective diabetes management tools is surging. HbA1c testing, which measures long-term blood glucose levels, is crucial for monitoring and managing diabetes and preventing its complications.

As countries invest in upgrading and expanding their healthcare facilities, the accessibility and quality of diabetes diagnostic services are improving. The increased availability of state-of-the-art equipment and improved healthcare delivery systems contribute to more efficient and widespread HbA1c testing.

The HbA1c testing industry is classified based on type, technology, end-use, and region.

The laboratory-based testing segment will grow rapidly through 2032, as they are considered the gold standard for HbA1c measurement due to their high accuracy and reliability. These tests utilize advanced techniques such as high-performance liquid chromatography (HPLC) and immunoassays to provide precise results, essential for effective diabetes management. The robustness of laboratory-based testing, along with its ability to handle high patient volumes and provide comprehensive diagnostic information, makes it a preferred choice for healthcare facilities.

The homecare segment will witness decent growth through 2032. With the increasing adoption of home monitoring devices, patients with diabetes are increasingly managing their HbA1c levels at home. The convenience of homecare testing devices allows individuals to track their glucose levels regularly, which is crucial for effective diabetes management. Innovations in home testing technologies, such as user-friendly glucose meters and HbA1c home testing kits, are making it easier for patients to perform tests and obtain reliable results without frequent visits to healthcare facilities.

Europe HbA1c testing industry size will expand at a steady pace through 2032, driven by the region's well-established healthcare infrastructure, coupled with high awareness levels about diabetes and its management. European countries are investing in advanced diagnostic technologies and enhancing healthcare services to improve diabetes care. Additionally, government initiatives and medical policies aimed at increasing diabetes screening and early detection are contributing to the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes
    • 3.2.1.2 Technological advancement
    • 3.2.1.3 Development of novel testing methodologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of devices
    • 3.2.2.2 Stringent regulatory policies
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Laboratory-based testing
• 5.3 Point-of-care (POC) testing

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Immunoassays
• 6.3 Chromatography
• 6.4 Enzymatic assays
• 6.5 Boronate affinity chromatography
• 6.6 High-performance liquid chromatography
• 6.7 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Homecare settings
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 ARKRAY, Inc.
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Ceragem Medisys Inc.
• 9.5 Danaher Corporation
• 9.6 EKF Diagnostics
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 HUMAN
• 9.9 Menarini Diagnostics s.r.l
• 9.10 PTS Diagnostics
• 9.11 Randox Laboratories Ltd.
• 9.12 SAKAE CO. LTD.
• 9.13 SEKISUI MEDICAL CO., LTD.
• 9.14 Siemens Healthineers AG
• 9.15 Trinity Biotech plc